Octagon Capital Advisors LP
An institutional investment manager in NEW YORK, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1839435.
- Reported value$1.11bn
- Positions27
Holdings: 27 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics IncDNTH | COM | 252828108 | 180 | 16.1% | 1,841,667 | Reduced−105,000 | |
| Definium Therapeutics IncDFTX | COM SHS | 24477V105 | 139 | 12.5% | 2,950,000 | Added+510,000 | |
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 132 | 11.9% | 993,000 | Added+316,000 | |
| Cogent Biosciences IncCOGT | COM | 19240Q201 | 90.9 | 8.2% | 2,350,000 | Unchanged | |
| Alumis IncALMS | COM | 022307102 | 79.7 | 7.2% | 2,830,700 | Unchanged | |
| Arrivent Biopharma IncAVBP | COM | 04272N102 | 68.5 | 6.2% | 1,971,054 | Unchanged | |
| Taysha Gene Therapies IncTSHA | COM SHS | 877619106 | 66.0 | 5.9% | 9,693,244 | Added+833,333 | |
| Bioage Labs IncBIOA | COM | 09077V100 | 42.8 | 3.9% | 1,748,000 | Unchanged | |
| Mirum Pharmaceuticals IncMIRM | COM | 604749101 | 39.7 | 3.6% | 338,900 | Unchanged | |
| Kymera Therapeutics IncKYMR | COM | 501575104 | 35.5 | 3.2% | 310,000 | Reduced−115,000 | |
| Aktis Oncology IncAKTS | COM | 01021M104 | 31.0 | 2.8% | 960,847 | Unchanged | |
| Xenon Pharmaceuticals IncXENE | COM | 98420N105 | 29.6 | 2.7% | 490,000 | Unchanged | |
| Erasca Inc | CALL | 29479A908 | 23.0 | 2.1% | 1,255,000 | Call | New+1,255,000 |
| Palisade Bio IncPALI | COM | 696389402 | 21.5 | 1.9% | 10,276,317 | Unchanged | |
| Ocular Therapeutix IncOCUL | COM | 67576A100 | 20.4 | 1.8% | 2,075,000 | Reduced−1,091,600 | |
| Disc Medicine IncIRON | COM | 254604101 | 19.7 | 1.8% | 270,000 | Unchanged | |
| Summit Therapeutics IncSMMT | COM | 86627T108 | 18.2 | 1.6% | 1,250,000 | New+1,250,000 | |
| Pharvaris N V | COM | N69605108 | 15.8 | 1.4% | 456,721 | Added+291,721 | |
| Adlai Nortye LtdANL | SPONSORED ADS | 00704R109 | 10.7 | 1.0% | 934,716 | New+934,716 | |
| Precision Biosciences IncDTIL | COM NEW | 74019P207 | 10.6 | 1.0% | 1,350,000 | Reduced−886,732 | |
| DBV Technologies S aDBVT | SPONSORED ADS | 23306J309 | 9.4 | 0.8% | 574,200 | Unchanged | |
| Faeth Therapeutics IncFTH | COM NEW | 81728A207 | 9.0 | 0.8% | 361,010 | New+361,010 | |
| Gyre Therapeutics IncGYRE | COM | 403783103 | 6.3 | 0.6% | 954,416 | New+954,416 | |
| Trevi Therapeutics IncTRVI | COM | 89532M101 | 5.9 | 0.5% | 315,000 | Reduced−1,170,000 | |
| Unicycive Therapeutics IncUNCY | COM NEW | 90466Y202 | 4.7 | 0.4% | 1,000,000 | Unchanged | |
| Context Therapeutics IncCNTX | COM | 21077P108 | 1.7 | 0.2% | 3,050,000 | Reduced−2,200,000 | |
| Gossamer Bio Inc | COM | 38341P102 | 1.3 | 0.1% | 7,750,000 | Unchanged |
Sold out: 7 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Bridgebio Oncology TherapeutBBOT | COM NEW | 107924102 | 0.0 | 0.0% | 0 | Sold out−719,000 | |
| Centessa Pharmaceuticals plc | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Sold out−750,000 | |
| Evommune IncEVMN | COM SHS | 30054Y107 | 0.0 | 0.0% | 0 | Sold out−143,472 | |
| Kalvista Pharmaceuticals Inc | COM | 483497103 | 0.0 | 0.0% | 0 | Sold out−1,450,000 | |
| Lexeo Therapeutics IncLXEO | COM | 52886X107 | 0.0 | 0.0% | 0 | Sold out−1,100,000 | |
| Perspective Therapeutics IncCATX | COM NEW | 46489V302 | 0.0 | 0.0% | 0 | Sold out−791,555 | |
| Terns Pharmaceuticals Inc | COM | 880881107 | 0.0 | 0.0% | 0 | Sold out−530,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0001839435-26-000004 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.